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Abstract 
Single or repetitive i.p. injections of Phytohemagglutinin (PHA) induced 
a selective marked decrease in blood and bone marrow lymphocytes in mice, 
suggesting that PHA might have a specific immunosuppressive effect. To test 
this hypothesis, parallel' experiments were conducted using female C57Bl/6J 
(H-2b) mice as recipients and either female C3H/HeJ (H-2k) or female (C57Blx 
C3He) Fl (H-2b,k) hybrid mice as donors of full-thickness skin grafts. 
lmmunosuppression, as indicated by prolonged graft life, was induced by 4s 
little as a single injection of 0.1 mg and increased with the dose to the 
maximum tolerated dose of 3.0 mg PHA. Several time and dose responses were 
tested. Maximal immunosuppression was induced using a regimen of 3.0 mg i.p. 
24 hrs. before grafting, followed by daily injection of 0.5 mg PHA i.p. 
These results lend support to the hypothesis that PHA, like anti-lymphocyte 
serum, has a specific suppressive effect on cel1-mediated immunity. 
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Introduction 
Renaissance painters have depicted attempts to allograft human tissues 
which occurred as early as the fourth century A.D. Through the years, many 
individuals have attempted grafts of heterogeneic (interspecies), allogeneic 
intraspecies), syngeneic (among identical twins or members of inbred strains) 
and autogeneic (within the same individual) materials with variable ~ucc~s.s. 
Advances in the fields of immunology and surgery within the last 25 years, 
however, have made it possible to transplant a full spectrum of organs and 
tissues. Allografts of bone, cartilage and blood vessels are now routinely 
performed. Grafts of this nature,however, are unique in that none of these 
three types of tissue is substantially antigenic (10,19). Sophisticated 
surgical techniques allow even the replantation of severed limbs and digits 
now with retention of at least partial function of the appendage (54). 
Further, it is technically possible to experimentally transplant a diverse 
spectrum of organs such as kidney, lung, liver, heart, pancreas, stomach and 
various endocrine glands (5,17,20,49,55,59). Clinically, though, only kidney 
allografts are routinely performed. 
Extensive work on the genetics of transplantation has shown that the 
success of transplants is determined by multiple histocomatibility genes 
designated by the letter H. These H genes express thems~lves as alloantigens, 
located primarily on cell surfaces, which incite a~ immune response when 
transferred into a host with antigenic specificities differing from those of 
the donor animal. In mice, analysis by linkage tests employing marker genes, 
and analysis by transplants from parental strains to their PI-hybrid off .. 
spring have shown that there are at least 15 H loci. Further, these have 
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been shown to be codominant, i.e., individually expressed in the heterozygote. 
The loci are widely distributed throughout the chro~somes and the majority 
of available evidence indicates that they are multiple allelic systems with 
many possible antigenic specificities for each locus. Histocompatibility 
loci also exhibit varying immunogenicity or strength; most impose only weak 
barriers to transplantation and are easily overcome or are not expressed on 
some genetic backgrounds. The H-2 locus, an extremely complex system of 
multiple alleles, presents the strongest transplantation barrier known in 
mice, and is seldom overcome even by tumor transplants (23). Familial studies 
of antigen distribution indicate that the situation in humans is analogous 
to that in mice (3,11), and definitive tests of histocompatibility have been 
developed which allow close matching of donors to recipients. 
Two factors remain the major obstacles preventing successful allograft-
ing of tissues and organs. Procedures for obtaining and preserving donor 
tissues for subsequent transplantation must first be improved. To this end, 
the use of cadaver donors seems to be the most promising; through the use of 
organ perfusion with chilled Ringer's solutions and storage at low tempera-
tures, the period of viability of many organs has been greatly extended and 
the destructive effects of post-mortem anoxia and autolysis minimized. These 
techniques now allow the use of cadaver kidney for transplantation and are 
being established for use with other organs (27). The second factor is the 
problem of inducing specific immune suppression of, the response to allogeneic 
materials without producing undesirable side effects. This difficulty in 
inducing specific immunosuppression is a consequence of the complex mechanism 
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of graft rejection and of the diffuse nature of the lymphoid and reticulo-
endothelial systems. According to Elves (12), the development of blood 
vessels between the graft and host during rejection of allografts is followed 
by migration of host mononuclear and neutrophil leucocytes into the graft. 
These cells include a high proportion of small lymphocytes which become sen-
sitized to the graft antigens probably by either of two means: (a) direct' 
interaction with soluble antigens that the graft has shed, or (b) indirectly 
by means of an RNA-like transfer factor liberated by macrophages which have 
ingested and processed antigenic graft materials. These sensitized lympho-
cytes then either leave the graft via the afferent lymphatics to the regional 
lymph nodes where they instigate a proliferative reaction resulting in the 
production of first more sensitized lymphocytes and finally antibody-contain-
ing plasma cells, or they remain in the graft where at some stage in rejec-
tion they probably transform into large pyrononophilic cells which have the 
ability to divide. It is likely that following division, these cells become 
mature plasma cells--this latter cell type appearing in large amounts when 
the graft is already necrotic. The small lymphocytes formed in the lymph 
nodes are released into the lymphatics and circulation from which some return 
to the graft and participate in the rejection reaction. From ~ vitro 
experiments, it appears that rejection is the result of direct cytocidal 
action on the part of the small lymphocytes, which may also contribute to the 
rejection by occluding the afferent blood supply to the graft. The plasma 
cells which appear in the lymph nodes and graft not only contain antibody to 
the graft donor's antigens, ,but are probably synthesizing it. This antibody 
seems, however, to play only a minor role in the allograft response; titers 
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very often rise only upon rejection of the graft, and such rises are unpre-
dictable. It is most likely that this antibody plays only an opsonic role 
and in itself is not a sufficient cause for graft rejection. Recently, 
Rapaport et a1. (43,44) have reported that a110grafting is associated with 
a marked rise in the level of circulating heterophile antibodies. They 
suggested on this basis that allograft rejection may be partly the result of 
an immune response to heterophile antigens in the graft tissue. This finding 
has also opened new alleys of investigation on the problem of autoimmunity. 
Further, lymphocytes and macrophages are widely distributed throughout the 
tissues of the body, necessitating that a systemic rather than localized 
treatment be used to achieve immunosuppression. 
The agents currently in use for inducing immunosuppression leave much to 
be desired because of their lack of specificity of suppression and the extent 
of their side effects. There are, according to Berenbaum (4) and Schwartz 
(47), four means by which immunosuppressive agents can act: enzyme inhibition 
template damage, structural damage, and mitotic inhibition. Accomplishment 
of anyone or a combination of these effects leads to reduced, unbalanced, 
or misdirected synthesis of cellular components and ultimately to cell death. 
The agents currently preferred, such as azathioprine, prednisone, actinomycin-
C, and X-irradiation, accomplish their purpose primarily as a result of the 
selectively greater sensitivity of the lymphoid syAtem compared to other 
tissues rather than as a result of any specifically unique sensitivity of the 
lymphoid system to these agents. In addition, Starzyl (51) has shown that, 
in kidney transplant patients, the patient with a rejection crisis and thus 
in most need of effective immunosuppressive therapy is also the most suscept-
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ible to the induction of irreversible bone marrow failure leading to infection 
and death. 
Another possible approach to immunosuppression is chronic thoracic duct 
drainage, a means of specifically eliminating or depleting the immunologically 
competent cells (i.e., small lymphocytes) and thereby rendering the host 
unreactive to allografts. Among others, Woodruff (64) through animal experi-
ments and Tilner et ale (56) through human therapy have shown this approach 
to be effective in delaying the onset of the allograft response. A disturbing 
note, however, is the observation that once rejection begins, it proceeds 
with the same rapidity and severity as an unimpaired response. This phenomeno 
and the limited extension of graft life obtained has limited the value of 
lymphocyte depletion as a primary means of specific immune suppression, but 
its value as an adjunct to other means is indicated by its additive effect 
on azathioprine"prednisone therapy in human renal allografting. 
To date, the only promising and apparently specific agent is anti .. 
lymphocyte serum (ALS). Many investigators have experimentally demonstrated 
the substantial suppressive effect of this agent on allograft immunity (22, 
29). On the other hand, considerable problems have been encountered in the 
use of ALS. Most conspicuous of these are the lack of a reliable test in 
, 
~ which correlates with ~~ effect and the problem of specificity of 
the ALS. A third problem is the side effects associated with protracted 
administration of the antiserum. There are four in vitro tests of ALS which 
have been extensively studied: (a) RBe agglutination, (b) lymphocyte agglu-
tination, (c) lymphocyte cytotoxicity (in presence of complement), and (d) 
lymphocyte transformation (RNA and DNA synthesis). As yet, none of these 
.6 
tests has been shown to reliably predict the!a~ immunosuppressive effect 
of ALS (63). Antigens with which ALS reacts are not only found in lympho-
cytes but are present in cells widely distributed throughout the body. It 
has been shown that even mouse tail skin epidermal cells can be used to 
elicit an active ALS. Seega1 et a1. (48) have observed a Masugi-type nephriti 
presumably due to rapid bind~ng of antibody to the glomeruli of the trans~ 
planted kidneys. Thus, the administration of ALS to prolong the life of allo-
grafts can lead to their eventual destruction as a result of a~tigens common 
to both graft tissue and lymphocytes. Serum sickness and anaphylactic 
reactions have complicated protracted administration of ALS and the eventual 
immune response to the foreign proteins of heterologous antisera limit the 
length of time for which they can be administered (30). The purification and 
use of anti-lymphocyte globulin (ALG) which is much less immunogenic than 
whole serum, however, has to an extent reduced these problems (63). Levey 
and Medawar have summarized in 12 points our present state of knowledge 
concerning anti-lymphocyte serum: 
1) ALS has the character of an antibody 
2) ALS does not act by enhancement 
3) The activity of ALS resides predominantly in the 7S fraction 
4) ALS is not directed against antigens peculiar to lymphoid cells 
5) Lymphoid cells are the effective targets'of ALS 
6) ALS does not act through lymphocytic depletion 
7) The state of unresponsiveness induced by ALS is not immunological 
tolerance 
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8) The immunosuppressive action of ALS is not a by-product of some 
more generalized organic damage 
9) The immunosuppressive effect of ALS outlives its own metabolic 
lifetime 
10) The effect of ALS on lymphoid cells persists through at least 
one cell division 
11) ALS is particularly effective in the homograft reaction 
12) ALS may act in the first instance on peripheral lymphocytes 
The attention of many investigators, particularly in the past few years, 
has been drawn to phytohemagglutinin (PHA) in the expectation that this com-
pound may have a specific suppressive effect on the allograft response in a 
manner similar to that of anti-lymphocyte serum. An aqueous extract of the 
leguminous plant Phaseo1us vulgaris, PHA and similarly obtained extracts 
from other plants of this genus have been known to researchers since Ehrlich 
used them in his studies of antigen-antibody interactions. 
There are two forms of Difco PHA (PHA-P and PHA-M) and a Burroughs-
Wellcome PHA which are available commercially. Rigas and Osgood (45) first 
described the extraction of PHA-M from the red kidney bean in 1955 and 
reported it to be a mucoprotein containing approximately 50% carbohydrate. 
, 
Pharmacologic activity was associated with the protein and in 1964, Rigas 
and Johnson (46) outlined the procedure for dissociating the protein moiety 
from the bulk of the polysaccharide under acid conditions. This preparation, 
which they labelled PHA-P, has approximately 50 times the erythro-agglutin-
ating activity of PHA-M. It has been determined experimentally by this 
investigator that this proportionality is also true with respect to the 
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induction of transformation of human lymphocytes ~ vitro and either the i.v. 
or i.p. LD50/48 hrs. PHA-P has been further shown to have a sedimentation 
coefficient of 6.5S, a diffusion coefficient of 4.8 cm2 sec·l xlO-7, 8 molec-
ular weight of 128,000 and an isoelectric point of pH 6.5. It is poor in 
sulfur-containing amino acids and rich in aspartic acid plus asparagine, 
serine, threonine and leucine; it has alanine as the only N-terminal amino' 
acid; it has a carbohydrate content of 3.4%. It is suspected but has not 
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been definitely shown that this carbohydrate is covalently linked to the 
protein moiety. There are at least 23 varieties of Phaseolus vulgaris, all 
of which yield hemagglutinins of somewhat similar activity upon aqueous 
extraction. Although the very great majority of work ~ !!!!2 and ~ ~ 
with both humans and animals has been carried out with the extract of the 
red kidney bean, occasional reports have been published using the phyto-
hemagglutinins from other varieties of Phaseolus vulgaris. These prepara-
tions all exert somewhat similar agglutinating activities, but they differ 
considerably in their toxicities and physical properties and may also differ 
in their mitogenic activities (53). Previous work from this laboratory has 
further shown that PHA-P varies considerably in activity from lot to lot as 
measured by the ~ vitro transformation of lymphocytes. 
In 1929 Goddard and Mandel published work which involved possible ~ 
vivo toxic effects of PHA in rabbits (21). Interest in PHA, however, 
remained only in its agglutinating pro~erties as a tool in preparing cel1-
free sera until 1960 when Nowell reported the mitogenic effect of PHA on 
peripheral blood leucocytes ~~ (40). Since then, several investigators 
have described the blastoid transformation of lymphocytes induced in vitro 
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by this substance (8,34). In addition, this blastoid transformation has 
been shown to be preceeded by an exponential acceleration of RNA, protein, 
and DNA synthesis. Bach and Hirschhorn (1) have reported a rise in the gamma 
globulin content of lymphocytic cells resulting from treatment ~ vitro of 
human lymphocytes with phytohemagglutinin. They suggested from this that 
this morphologic transformation of lymphocytes arises as an immunologic ' .. 
reaction to PHA acting as a non-specific antigen and stimulating antibody 
production. Similarly, Elves et ale (14) reported detectable amounts of 
gamma globulin arising in transforming human small lymphocytes subsequent to 
treatment ~ vitro with PHA or antigens. Since then, however, other authors 
have demonstrated that PHA stimulates all classes of RNA and protein and 
DNA (32,36) suggesting that the lymphocytes' resfonse to PHA differs biochem-
ically from their response to antigens. It is interesting that, as mentioned 
above, anti-lymphocyte serum has also been shown to induce blastoid trans-
formation in peripheral blood lymphocytes ~ vitro even though this property 
of ALS is not a requisite for immunosuppression in ~ (63). 
Phytohemagglutinin has been used in patients with aplastic anemia in the 
attempt to restore their bone marrow cellularity (16,26,60). PHA has also 
been used in the Veterans Administration Hospital, Hines, Illinois on two 
• patients with bronchogenic carcinoma treated by external irradiation (52). 
Few experiments have been conducted on laboratory animals in the attempt of 
proving the validity of the clinical treatment. Elves et ale (15) failed 
to demonstrate any consistent effects in rats after one or repetitive i.v. 
or i.p. injections of PHA. Papac (41) reported that mice and rats exposed 
to varying doses of irradiation failed to show stimulation of marrow regener-
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ation after treatment with the highest tolerated. doses of PHA administered 
i.v. 
The possibility of an immunosuppressive effect of phytohemagglutinin has 
been previously suggested by the work of CaIne and Wheeler (9). In a pre-
liminary report, they observed following combined treatment with PHA and 
azathioprine a moderate prolongation of the life of renal allografts. These 
authors noted a slight immunosuppressive activity of PHA alone and a poten-
tiation of the effect of the Imuran. In addition, ~o recent papers, one by 
Spreafico et a1. (50) and the second by Elves (13), have shown that phyto-
hemagglutinin can suppress antibody synthesis ~~. Following the i.v. 
administration of this compound to rats, these authors noted a decrease in 
the amount of hemolytic antibody formed during the primary and secondary 
immune response to chicken or sheep red blood cells. 
Using skin allograft rejection in mice as a marker of immune competence, 
the present work was undertaken to answer the following three specific 
questions: 
1) What is the effect of phytohemagglutinin on cell-mediated immunity 
as measured by prolongation of the life of mouse skin allografts 
following i.p. administration of PHA? 
2) What is the optimal dose and most effective schedule of administra-
tion of this preparation in prolonging mouse skin allograft life? 
3) What is the relationship of the ~ !!!2 effects of PHA to the 
in vitro action of this compound? 
11 
Material and Methods 
Animals. Adult female CFI mice eight to ten weeks of age (Carworth 
Farms Inc.) were used for the blood and bone marrow studies. It was felt 
that a disparity across the H-2 locus would provide the most definitive test 
of immunosuppression. Accordingly, adult female C3H/HeJ (H-2b) mice eight 
to ten weeks of age and adult femaleC57BL/6J (H-2k) mice of the same age-' 
(Roscoe B. Jackson Memorial Laborator1es) were used for these experiments. 
Also used in this study were eight to ten weeks old adult female (C3H x 
C57) F1 (H-2b,k) hybrid mice bred from the above stocks. 
Phytohemagglutinin. Each vial containing 100 mg phytohemagglutinin-P 
(PHA-P, Difco lot nos. 497992 and 496843) was diluted with 5.0 ml sterile 
isotonic saline. For the several doses of PHA used in this study, dilutions 
were made with sterile isotonic saline to the desired amounts of PHA per 
0.5 cc, the amount of fluid injected i.p. 
Absolute and differential counts. Blood samples were taken from the 
tail veins of mice. Smears were made, stained with Wright's stain, and 100 
cells counted to establish a differential count. According to standard 
hematologic procedure (61), blood samples were diluted in a WBC serologic 
pipette with a 3% solution of HCl and New Methylene Blue to hemolyze the RBC 
and counted in a hemacytometer to determine the absolute WBC. From these 
two counts, the absolute number of lymphocytes was· calculated. Blasts and 
mitoses in the bone marrow were counted as part of the differential. 
Skin grafting. Adopted for this tudy was a modification of the method 
described by Medawar using full-thickness skin grafts (33). Twenty-four 
hours before grafting, the donor animal and prospective recipients were 
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closely shaved with an electric clippers, number 40 head. Immediately prior 
to grafting, the donor animal was sacrificed by cervical dislocation and 
• 
skinned using aseptic technique. The skin was then stretched out inner side 
up at even tension, flushed with sterile saline, scraped free of fat and 
fascia with a sterile number 11 scalpel, and from 20 to 30 circular grafts 
1.0 cm in diameter were cut using a sterile cork borer. These grafts were 
then placed between filter paper wet with sterile saline at 40 C until use. 
While being held in the investigator's left hand, each recipient mouse was 
lightly anesthetized using an ether nose cone, and a bloodless circular graft 
bed to the level of the panniculus carnosus was prepared on the ventral chest 
wall using a s~a11, sharply pointed, curved scissors. First, make a nick at 
the posterior end of the bed site with the point of the scissors. Next, 
reverse the scissors and free the skin from the underlying tissue by sliding 
them through the nick and under the skin then spreading the points slightly. 
Lastly, cut a circular piece of skin 1 em in diameter to expose the panniculus 
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carnosus. The graft was placed in position, rotated 180 from normal hair 
direction, and the edges of the graft apposed evenly and symmetrically to the 
edges of the bed. No sutures were used; the graft was held in place by means 
of an overlay of vaseline impregnated gauze and a dressing of adhesive tape. 
The animals were housed two per cage for seven days postoperatively, at which 
time the dressings were removed and a loose dressing of gauze and scotch tape 
placed on the animal for 24 hours. When this final dressing was removed, 
the animals were housed five per cage and examined daily for evidence of 
graft rejection. 
Graft rejection. Complete rejection of the graft was taken as the end 
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point of each experiment. This was determined by visual inspection of the 
grafts in ~ according to criteria established by Billingham et a1. (6). 
Experimental procedure. Each experiment was designed and carried out 
. 
as discussed in the results. Each point on the charts of the experimental 
graft groups represents 15 to 20 mice (average graft survival ± one S.D.) 
and there are 30 to 40 mice represented by the plots of control graft survival 
± one S.D. All blood and bone marrow studies are shown with 95% confidence 
limits. Each experimental group contains at least 5 animals and the control 
groups contain 10 to 15 animals. No animals were bled more than one time. 
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Results 
The first experiment was designed to test the effect of a single 3.0 mg 
dose of PHA as a function of time between administration of the PHA and graft-
ing. As can be seen in Figure I, PHA given from 30 minutes after to three 
days before grafting induces in the C3H to C57 system a significantly longer 
graft survival (10.4 days S.D. ± 1.0) compared to the control graft survival 
(8.3 days S.D. ± 0.4). PHA had only a small effect on graft survival if 
given four days before grafting--the period of time shown in Figure 2 to 
correspond with the time of lymphopenia induced in CFl mice by the same dose 
of PHA. 
Next, the effect of daily repetitive injections of 1.5 mg PHA i.p. was 
tested. Again, a better graft survival was noted in the PHA treated group 
than in the control group, seen in Figure 3. However, a slightly better 
graft survival followed the single injection of PHA (10.5 days S.D. + 0.7) 
rather than the repetitive injections, decreasing to a minimum value in the 
four injection group (9.5 days S.D. + 0.8). 
Several experiments were then performed to investigate the dose-depend-
ence of skin graft life following a single injection of PHA i.p. In these 
experiments, both the C3H to C57 and the Fl-hybrid to C57systems were used. 
Figure 4 shows that the average graft life was significantly prolonged in the 
C3H system by treatment with PHA, but did not vary'significantly over the 
dose range tested (10.3 days S.D. ± 0.5). Even the small dose of 0.1 mg 
significantly increased the graft survival '(10.2 days S.D. + 0.4) as compared 
-
to the survival of control grafts '(8.3 days S.D. ± 0.4). A different response 
was observed in the Fl-hybrid to C57 system. Here there was a direct correl-
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ation between dose and survival, higher doses affording longer survival. No 
correlation between graft survival time and peripheral blood lymphopenia was 
observed in this experiment. Table 1 relates the changes in absolute blood 
lymphocyte levels to graft survival and dose of PHA used. It is apparent 
from this table that the immunosuppressive effect of PHA is not dependent 
upon the production of peripheral blood lymphppenia. A further observation 
is that the relative percentage of blasts ·and mitoses in the bone marrow of 
CFl mice following a single injection of 3.0 mg PHA i.p. (Fig. 5).rise con-
commitantly with the changes in the peripheral blood lymphocyte level. 
Maximal prolongation of allograft survival has been obtained with the 
following treatment. First, one injection of 3.0 mg PHA was given intra-
peritoneally 24 hrs. before grafting. The graft was followed by daily injec-
tions of 0.5 mg PHA starting one day postoperatively and extending from two 
injections up to 14 injections in the C3H system or 24 injections in the 
Fl-hybrid system, i.e., the time of complete rejection in the two systems. 
Plotting graft survival against the number of daily injections, Figure 6 
shows that there is again a disproportionate response in the C3H system with 
respect to small doses of PHA while there is an approximately proportionate 
response in the Fl-hybrid system. In both systems, however, the maximum 
graft life obtained is approximately 100% better than the control (14.0 days 
S.D. ± 0.9 versus 8.3 days S.D. + 0.4 with C3H donors, and 23.9 days S.D. ± 
1.2 versus 10.3 days S.D. ± 0.6 with F1-hybrid donors). In all instances 
the survival of grafts in the control group were significantly less than 
those in the treated groups. 
It is interesting that the degree and rapidity of rejection, once begun, 
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Table 1. 
COMPARISON OF GRAFT SURVIVAL AND ABSOLUTE 
LYMPHOCYTE LEVELS AS A FUNCTION OF SINGLE 
DOSE OF PHA-P I. P. 
Dose PHA 
mg. I. P. 
0.1 
0.3 
1.0 
3.0 
No T. 
._-_._ .. __ ._----.-
.. --
Prolongation 
Graft Life % 
C3B Fl 
22.8 5.6 
'. 
26.5 22.3 
21.7' 35.9 
25.3 38.8 
-
• __ ,_ -4 ______ ••• _ •• _. _ 
Absolute Blood Lymphocyte Count 
cells/mm3 
2 days 4 days 7 days 
9,500 
12,200 
8,550 
. 2,800 
14,500 
15,850 
9,750 
3,950 
6,600 :I: 2,500 
4,500 
10,900 
9,350 
9,200 
C57BL/6 temale mice were used. tor this blood study'. N. animal was 
used. more than once; there oe f'1 .... mice represented by each average 
value. The control value is an average .t 15 m1oe, 5 bled en each 
of' the three days shown, and the 95~ oonfidenoe limit is given. 
, . 
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was unaffected by the PHA treatment, and resembled the rejection process in 
the control animals. Further, in all experiments, no deaths could be attrib-
uted to the toxicity of PHA. Extensive work with 12 week old female CFl mice 
has shown that the LD50 at 48 hrs. for PHA-P injected intraperitoneally is 
. 
9.5 mg. Due to the differences in weight between the CFl and C57BL strains, 
this corresponds to an LD50 of 6.0 mg for the eight to ten week old CS7BL 
mice used as graft recipients. 
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Discussion 
Extensive investigation of alternate methods of skin grafting found them 
to be unsuitable for the purposes of this study before the procedure described 
above was adopted. This method is recommended by many considerations. The 
technique is quite simple and no sutures are needed to position the graft. 
This results in practically eliminating the problem of infection due to exper-
imental procedures. Second, this technique is reliably and quickly performed; 
less than 10% of the animals have to be discarded as a result of technical 
error such as uncontrolled bleeding in the graft bed or movement of the graft 
once it is in place. Third, many grafts can be obtained from a siqgle animal, 
thereby minimizing the possibility of antigenic variation being introduced 
by large numbers of dpnor animals. Fourth, there is no loss or alteration 
of graft antigenicity for periods of time up to 6 hrs. as a result of the 
methods used to prepare and store the skin grafts until use (62). Fifth, 
the uniform graft size insures both a more uniform antigenic challenge to the 
recipient animal and a consequently more uniform immune response to the graft 
antigens. Galton (18) has shown that with grafts from F1-hybrids to either 
parent or with grafts across non-H-2 loci, larger grafts have slightly shorter 
survival times, indicating that in these systems, at least, the antigenic 
dose to which the animal is exposed can be a significa~t variable. 
In the above experiments, PHA-P injected intraperitoneally has been 
shown to increase the survival of skin allografts in mice to a maximum value 
of 71% in the e3H to e57 system and 132% in the Fl-hybrid to e57 system. 
The maximum graft survivals obtained compare well with results obtained using 
other current immunosuppressive agents. Hoehn (27) using A to eBA (an H-2 
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difference) grafts as his "strong" system and C3H to CBA (a non-H-2 difference 
as his "weak" system obtained a 20% and 50% respective increase in graft 
survival using paired Imuran and Actinomycin C therapy. These results, 
however, were accompanied by a 60 to 70% mortality due to drug toxicity. 
, 
Treatment with bromodeoxyuridine and thioguanine in the "strong" system 
resulted in a 60% increase in graft survival with a mortality of 13.3%. No 
animals which succumbed~to the effects of the therapy were included in the 
calculation of graft survival. Considerably better results were achieved by 
Levey and Medawar (30) using anti-lymphocyte serum to prolong the life of 
A strain skin grafts on CBA mice. They reported a 134% prolongation of graft 
life as compared to control graft survival with no apparent toxic effects due· 
to the ALS. Thus, it would seem that the results obtained with PHA compare 
well with results achieved through other means of chemical suppression. In 
addition, PHA, like anti-lymphocyte serum, exerts its effects unaccompanied 
by any apparent toxic side effects. 
Initial studies of blood and bone marrow cell levels following treatment 
with PHA suggested to us that the lymphopenia produced in both the peripheral 
blood and bone marrow could lead to a delay in the allograft response. 
During the course of this study, however, it became apparent that this phen-
omenon was inadequate to explain the longevity of allografts following treat-
ments with PHA over the dose range and regimens .tested. Although the length 
of time during which prolonged graft life could be induced following a single 
injection of PHA corresponded to the duration of peripheral blood lymphopenia, 
grafts performed 30 minutes before or after injection of PHA also exhibited 
a similarly prolonged survival. This was interesting in that these grafts 
26 
were performed before the period of lymphopenia became evident. More reveal-
ing was the observation that graft life far outlasted the periods of lympho-
penia in either the peripheral blood or bone marrow. That lymphopenia pro-
duction is not the mode of action of PHA in suppressing allograft rejection 
was conclusively established by the dose-response experiment in which it was 
shown that doses of PHA which induced a pronounced lymphocytosis also 'induced 
a marked prolongation of graft survival. These results are further supported 
by the observation that the relative number of blasts and mitoses in the bone 
marrow rise following treatment with PHA. What seems likely in the light of 
these experiments is an explanation offered by Elves (13) who suggested that 
"transformation of immunologically competent cells occurs in .Y!Y2. with the 
'siphoning off' of such cells so that they are not available to react ,,71th 
the immunizing antigen", in this case the allograft. The present study 
supported this idea and suggested further insights into the. mechanism by which 
the immunosuppression was induced by PHA. From the studies of peripheral 
blood and bone marrow following the administration of PHA, it appeared that 
this compound acts on two distinct populations of lymphocytes in suppressing 
allograft rejection. The most important action of PHA is exerted primarily 
on the central lymphocytes' through the transformation and subsequent "siphon-
. 
ing off" of immunocompetent cells. This was evidenced by our Own observation 
of the rise in the numbers of bone marrow blasts· and mitoses following injec-
tion of PHA and by Elves (15) who noted an increase in the mitotic activity 
in the spleens of mice following injection of PHA. A secondary action of 
PHA, apparent only after higher doses, is the induction of lymphopenia in the 
peripheral blood. This effect seemed to result from either a direct cytocidal 
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action of PHA or enhanced phagocytosis and clearance of circulating 1ympho-
cytes due to PHA-induced 1eukoagg1utination and was observed to make only'a 
small addition to the prolongation of graft life accomplished by non-lympho-
penia doses of PHA. 
I 
Many investigators have attempted to clarify the importance of and the 
interrelationships between the three observed activities of phytohemagglutinin: 
(a) erythroagglutination, (b) leuko~gglutination, and (c) stimulation of the 
blastoid transformation of lymphocytes. Barkhan et al. (2), using red cel~ 
absorption, and Tunis (57), employing selective heat inactivation to eliminate 
the red cell agglutinin, showed that this activity of PHA was not necessary 
to the ~ vitro blastoid transformation of lymphoid cells. Early attempts 
at separating the white cell agglutinin from the lymphocyte mitogen failed, 
however, and led to speculation that the b1astoid transformation induced by 
PHA was merely the result of cell membrane changes following agglutination 
(24,40). As discussed in the introduction to this thesis, subsequent work 
indicated that pHA may act as a non-specific antigenic challenge in inducing 
blastoid transformation. More extensive work has shown this theory to be an 
inadequate explanation. Recently, Weber et al. (58) using ion exchange 
chromatography to separate the 1eukoagglutinating and lymphocyte-stimulating 
activities of PHA, and Borjeson et a1. (7) using Vi polysaccharide to e1im-
inate the agglutination of leukocytes, have shown the leukocyte mitogen to 
be physically distinct and independent of the leukocyte and erythrocyte 
agglutinins. A possible explanation of the basis for the mitogenicity of 
PHA, although unsupported by direct experimental evidence, is that PHA may 
act on a basic control mechanism of RNA synthesis leading to the eventual 
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blastoid transformation of the lymphocyte. Incidentally, this process may 
be similar to the mechanism of antigenic induction of antibody synthesis as 
suggested by a result of Spreafico and Lerner (50) who observed that PHA, 
while transiently suppressing the primary and second~ry hemolysin response 
I 
to sheep RBC, enhanced the normal background reactivity of non-immunized mice 
to this antigen. The idea of PHA acting through a basic inductive st~p in 
the metabolism of the cell is not new. Mueller and LeMahieu (36) have sug-
gested that PHA may act primarily to counteract normal repressor mechanisms 
regulating RNA synthesis. Recently, Rabinowitz and Dietz (42) studying the 
induction of lactate dehydrogenase (LDH) and malate dehydrogenase (MDH) 
isozymes by PHA, concluded that "PHA acts at the two genetic loci controlling 
synthesis of muscle and heart-type (M and H) lactate dehydrogenase polypep· 
tide subunits". They further stated that "the synthesis of the two isozymes 
of malate dehydrogenase also may be under the control of separate genes which 
in granulocytes are influenced by conditions of cell culture, rather than by 
phytohemagglutinin". Suggested as a means by which PHA accomplishes these 
results was that it "may act at allosteric sites on protein repressors or in-
ducers of operator genes for the M- and H-type polypeptides •••••••• ". This 
postulated mechanism of action of PHA is consistent with the view that this 
compound parallels in many respects the action of hormones which act on many 
sites on a variety of functionally different proteins. 
In this thesis it has been shown that PHA-P given intraperitonea1ly is 
effective in suppressing the rejection of allografts across the H-2 locus in 
mice. A regimen of one large dose of PHA prior to grafting followed by small 
daily injections of this compound has been shown to yield results comparable 
29 
. 
to those obtained with other immunosuppressive agents. Significantly, this 
immunosuppression was not accompanied by any mortality or apparent toxic 
effects of the PHA. Studies of the blood and bone marrow suggest that the 
suppressive\activity of PHA ~ ~ is not related to a lymphopenic effect 
but is probably the result of the lymphocyte mitogen. It thus appears that 
PHA is comparable to anti-lymphocyte serum in its effectively specific 
suppression of allograft rejection and its lack of toxicity in the treated 
animal. Comparing what is known of PHA to some of the points made by Levey 
and Medawar (30) concerning anti-lymphocyte serum, it can be said that: 
1) Lymphoid cells are the effective targets of both PHA and ALS. 
2) Neither ALS nor PHA act through lymphocytic depletion. 
3) The states of unresponsiveness induced by either PHA or ALS are 
not immunological tolerance. 
4) The immunosuppressive actions of PHA and ALS are not the by-products 
of some more generalized organic damage. 
5) PHA, like ALS, is particularly effective in the homogra.ft reaction, 
inducing only a transient suppression of the humoral immune 
response (38,50). 
6) While ALS appears to act in the first instance on peripheral lympho-
cytes, experimental evidence indicates that PHA may act on the 
central lymphoid orgons. This last paint raises the interesting 
speculation that combined PHA-ALS therapy may be particularly 
effective and non-toxic in preventing allograft rejection in the 
clinical situation. 
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